Zacks Research Issues Pessimistic Forecast for PCRX Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Stock analysts at Zacks Research cut their FY2024 earnings per share estimates for Pacira BioSciences in a research report issued to clients and investors on Tuesday, February 11th. Zacks Research analyst R. Department now anticipates that the company will earn $2.61 per share for the year, down from their previous estimate of $2.63. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q4 2024 earnings at $0.59 EPS, Q1 2025 earnings at $0.63 EPS, Q2 2025 earnings at $0.68 EPS, Q3 2025 earnings at $0.66 EPS, Q4 2025 earnings at $0.68 EPS, FY2025 earnings at $2.66 EPS, Q1 2026 earnings at $0.65 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.67 EPS and FY2026 earnings at $2.83 EPS.

Other research analysts also recently issued research reports about the company. Needham & Company LLC upped their price objective on Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, January 13th. HC Wainwright restated a “buy” rating and issued a $39.00 price objective on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price objective for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Royal Bank of Canada reiterated a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, Barclays cut their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $22.78.

Pacira BioSciences Trading Down 2.2 %

Shares of Pacira BioSciences stock opened at $26.53 on Friday. The company has a market capitalization of $1.22 billion, a P/E ratio of -13.07 and a beta of 0.80. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The stock has a fifty day simple moving average of $21.72 and a 200 day simple moving average of $18.06. Pacira BioSciences has a 12-month low of $11.16 and a 12-month high of $31.67.

Institutional Trading of Pacira BioSciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC grew its position in Pacira BioSciences by 779.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock worth $26,000 after acquiring an additional 1,208 shares during the last quarter. Caitlin John LLC grew its position in shares of Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after buying an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC grew its position in shares of Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after buying an additional 2,749 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after buying an additional 513 shares during the last quarter. Finally, CWM LLC grew its position in shares of Pacira BioSciences by 713.6% in the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock worth $98,000 after buying an additional 5,716 shares during the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.